Warhound Raised 200 Million Dollars to Genetically Engineer a Better Military Dog
Texas startup Warhound, from Anduril cofounder Palmer Luckey and Colossal Biosciences cofounder Ben Lamm, has 200 million dollars in seed funding to engineer and clone healthier military dogs, with the first pups expected early next year.
Two billionaire founders, one unusual animal
In what Morning Brew calls the beginning of a werewolf movie, two billionaires are teaming up to genetically engineer a better breed of military dog. Texas based startup Warhound was publicly revealed on Thursday and has already secured 200 million dollars in seed funding, at a valuation of about 1.2 billion dollars.
The startup was launched by Palmer Luckey, cofounder of defense technology company Anduril, and Ben Lamm, cofounder of Colossal Biosciences, the company best known for trying to bring back extinct species like the woolly mammoth. That pairing explains the shape of the company: one founder builds technology for the military, the other builds living animals in a lab.
What engineering a working dog means
Per TechCrunch reporting shared by Morning Brew, Lamm company will help engineer and clone healthier, hardier dogs, free of performance hindering problems like poor eyesight and hip dysplasia. The dogs will also be optimized for useful traits, like bomb sniffing. Luckey side of the partnership outfits the dogs with cutting edge technology, including goggles and protective vests.
Warhound says it has partnered with the American Humane Society to ensure the care and well being of every dog. That partnership will be watched closely, because engineering animals for war raises questions that a vest cannot answer. The company is presenting the work as breeding with better tools: remove the inherited problems that end careers early, and strengthen the traits the work already selects for.
The supply problem is real
The business case rests on scarcity. According to Warhound, working dogs are hard to come by. The United States military has to acquire about 80 percent of its dogs from Europe, and fewer than half of the dogs actually end up deemed fit for service, often due to health issues.
Read that as a manufacturing problem in living form. A buyer depends on foreign supply, waits through a long raising and training process, and then rejects more than half the output at the final inspection. A company that promises healthier dogs, born closer to home, with a higher pass rate, is selling yield as much as it is selling genetics. That is why investors are paying attention before a single engineered dog has reported for duty.
Investors are buying the platform, not the puppy
Warhound is backed by Sequoia, ARK Invest, a CIA backed investment fund, and more. A 200 million dollar seed round for dogs sounds absurd until it is read as a platform bet. Colossal cloning and engineering pipeline, proven on headline species like the mammoth project, would gain a defense customer with recurring demand. Anduril distribution into military programs would gain a living product line no software competitor can copy quickly.
Lamm told TechCrunch he expects the first engineered pups to be born early next year. That date is the first real test. Until then, Warhound is a valuation built on a supply problem, two famous founders, and a promise. The promise is plausible. It is not yet a product.
The lesson under the strange headline
Strip away the science fiction surface and a familiar startup pattern remains. Find a buyer with a painful, expensive, ongoing supply problem. Show that most of the cost sits in failure and rejection, not in the successful unit. Then build the thing that reduces the failure rate, and price it against the waste it removes.
Creators and service businesses run a smaller version of the same math. Most of the cost in event coverage, video production, or client work is not the finished deliverable. It is the rework, the missed handoff, and the job that almost fit. Warhound is a reminder, at billion dollar scale, that reducing failure is a product people pay a premium for.
Sources and further reading
Sources were checked for this article. Tool features, prices and availability can change. Product claims are attributed to their publishers.
